SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by:
Nordic Bioscience A/S
ClinicalTrials.gov Identifier:
NCT00486369
First received: June 13, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted
  Purpose

The purpose of this study is to expose patients with OA to calcitonin and to determine plasma calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin. Also the purpose is to assess the effect of different doses of oral calcitonin (0.6 mg and 0.8 mg oral) compared to placebo on serum CTX-I and CTX-II. Finally to assess the tolerance profile of different doses/formulations of oral calcitonin compared to placebo.


Condition Intervention Phase
Osteoarthritis
Drug: Oral salmon calcitonin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.

Resource links provided by NLM:


Further study details as provided by Nordic Bioscience A/S:

Secondary Outcome Measures:
  • Changes in Urine CTX-I and CTX-II
  • Changes in serum osteocalcin and serum CTX-I
  • Number of adverse events

Study Start Date: January 2007
  Eligibility

Ages Eligible for Study:   52 Years to 75 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Medical history and symptoms of knee osteoarthritis

Exclusion Criteria:

  • Any other disease or medication affecting the bone or cartilage.
  • Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00486369

Locations
Denmark
CCBR A/S
Ballerup, Denmark, 2750
Sponsors and Collaborators
Nordic Bioscience A/S
Novartis
Investigators
Study Chair: Bente J Riis, M.D. Nordic Bioscience A/S
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00486369     History of Changes
Other Study ID Numbers: CSMC021C2102
Study First Received: June 13, 2007
Last Updated: June 13, 2007
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Nordic Bioscience A/S:
Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers

Additional relevant MeSH terms:
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Salmon calcitonin
Calcitonin
Calcitonin Gene-Related Peptide
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014